Biocon
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Biocon entered into a global settlement and license agreement with Genentech to resolve pending patent disputes in the United States, Canada and other jurisdictions over Pebrilzo, its biosimilar to Perjeta (pertuzumab). The agreement secured the earliest licensed launch dates of the first quarter of calendar 2027 in the European Union and the United Kingdom, the third quarter of calendar 2028 in the United States, and calendar 2026-2028 in rest-of-world markets, with launches subject to regulatory approval. Pebrilzo, a 420 mg pertuzumab infusion for HER2-positive breast cancer, had received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on 21 September 2026. Biosimilars accounted for about 66% of Biocon's operating revenue in the June quarter. The company reported gross revenue of about ₹17,270 crore for the year to March and operates seven manufacturing and three research sites across more than 120 countries.
Powered by Tijori
Biocon entered into a global settlement and license agreement with Genentech to resolve pending patent disputes in the United States, Canada and other jurisdictions over Pebrilzo, its biosimilar to Perjeta (pertuzumab). The agreement secured the earliest licensed launch dates of the first quarter of calendar 2027 in the European Union and the United Kingdom, the third quarter of calendar 2028 in the United States, and calendar 2026-2028 in rest-of-world markets, with launches subject to regulatory approval. Pebrilzo, a 420 mg pertuzumab infusion for HER2-positive breast cancer, had received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on 21 September 2026. Biosimilars accounted for about 66% of Biocon's operating revenue in the June quarter. The company reported gross revenue of about ₹17,270 crore for the year to March and operates seven manufacturing and three research sites across more than 120 countries.
Powered by Tijori
Investors, policymaker flag AI's threat to humanity
Singapore minister, Biocon founder warn of loss of control, bioweapons
Billionaire investor Dalio cautions AI bubble close to bursting
By Ankur Banerjee
SINGAPORE, Oct 7 (Reuters) - Existential and financial risks posed by the artificial intelligence boom were top of mind for investors and policymakers at two conferences in Singapore on Wednesday, highlighting a cautious shift in mood around the AI trade.
Concerns that once centred on frothy valuations have broadened into a wide swathe of fears, including autonomous systems slipping out of human control, AI-designed bioweapons and the possibility that massive spending on the technology may never pay off.
"Anyone who tells you I've got absolute control over my autonomous agent... obviously doesn't know what he's talking about. So loss of control is a real threat," Singaporean Foreign Minister Vivian Balakrishnan said at the Milken Institute Asia Summit.
Last month, the heads of leading US AI labs came together in a rare show of unity to call for slowing the technology's development, warning it could soon improve on its own and slip beyond human control.
Claude maker Anthropic plans to caution potential investors in its IPO that advanced AI could pose "catastrophic or existential risks to humanity," Reuters reported last week.
Balakrishnan said on Wednesday the risk of state and non-state actors using the technology to build new weapons, "whether it's in chemistry or biology or in weapons of mass destruction, is very real."
Kiran Mazumdar-Shaw, founder and chairperson of Indian biopharmaceutical firm Biocon BIOC.NS, said that while AI was a force for good, bad actors could use it to design new viruses or pathogens.
"The real existential threat is bioterrorism," she said at the Forbes Global CEO Conference, calling for guardrails and governance. "I don't think self-governance is going to work."
BUBBLE WORRIES LINGER
Investors' faith in the AI trade has propped up the stock market even as higher energy prices and episodic routs in the bond market have pushed borrowing costs in major economies to multi-decade highs.
But worries over how long the AI rally can last and what it means for global markets have persist.
"If the AI narrative is unwound because of safety issues, regulation or because as we go through 2027, end users don't see sufficient ROI (return on investment), there could be issues," said Rohit Sipahimalani, chief investment officer at Singapore state investor Temasek TEM.UL.
"The biggest risk to the market is the AI narrative. Right now, it seems very strong," Sipahimalani said at the Milken Institute event.
Bridgewater Associates founder Ray Dalio was less sanguine, saying AI was in a "classic bubble" and there was a difference between "how terrific a technology is and how terrific an investment is."
He told the Forbes event that rising rates and changing circumstances had not "yet had a negative effect on other things," but that there was pressure for interest rates to rise further.
Once higher rates began to bite, the bubble would start to burst, Dalio said. "I think we're close to that."
(Reporting by Ankur Banerjee, Tom Westbrook and Xinghui Kok in Singapore, editing by Xevi Fontdegloria)
(([email protected];; Mobile - +65 8121 3925;))
Investors, policymaker flag AI's threat to humanity
Singapore minister, Biocon founder warn of loss of control, bioweapons
Billionaire investor Dalio cautions AI bubble close to bursting
By Ankur Banerjee
SINGAPORE, Oct 7 (Reuters) - Existential and financial risks posed by the artificial intelligence boom were top of mind for investors and policymakers at two conferences in Singapore on Wednesday, highlighting a cautious shift in mood around the AI trade.
Concerns that once centred on frothy valuations have broadened into a wide swathe of fears, including autonomous systems slipping out of human control, AI-designed bioweapons and the possibility that massive spending on the technology may never pay off.
"Anyone who tells you I've got absolute control over my autonomous agent... obviously doesn't know what he's talking about. So loss of control is a real threat," Singaporean Foreign Minister Vivian Balakrishnan said at the Milken Institute Asia Summit.
Last month, the heads of leading US AI labs came together in a rare show of unity to call for slowing the technology's development, warning it could soon improve on its own and slip beyond human control.
Claude maker Anthropic plans to caution potential investors in its IPO that advanced AI could pose "catastrophic or existential risks to humanity," Reuters reported last week.
Balakrishnan said on Wednesday the risk of state and non-state actors using the technology to build new weapons, "whether it's in chemistry or biology or in weapons of mass destruction, is very real."
Kiran Mazumdar-Shaw, founder and chairperson of Indian biopharmaceutical firm Biocon BIOC.NS, said that while AI was a force for good, bad actors could use it to design new viruses or pathogens.
"The real existential threat is bioterrorism," she said at the Forbes Global CEO Conference, calling for guardrails and governance. "I don't think self-governance is going to work."
BUBBLE WORRIES LINGER
Investors' faith in the AI trade has propped up the stock market even as higher energy prices and episodic routs in the bond market have pushed borrowing costs in major economies to multi-decade highs.
But worries over how long the AI rally can last and what it means for global markets have persist.
"If the AI narrative is unwound because of safety issues, regulation or because as we go through 2027, end users don't see sufficient ROI (return on investment), there could be issues," said Rohit Sipahimalani, chief investment officer at Singapore state investor Temasek TEM.UL.
"The biggest risk to the market is the AI narrative. Right now, it seems very strong," Sipahimalani said at the Milken Institute event.
Bridgewater Associates founder Ray Dalio was less sanguine, saying AI was in a "classic bubble" and there was a difference between "how terrific a technology is and how terrific an investment is."
He told the Forbes event that rising rates and changing circumstances had not "yet had a negative effect on other things," but that there was pressure for interest rates to rise further.
Once higher rates began to bite, the bubble would start to burst, Dalio said. "I think we're close to that."
(Reporting by Ankur Banerjee, Tom Westbrook and Xinghui Kok in Singapore, editing by Xevi Fontdegloria)
(([email protected];; Mobile - +65 8121 3925;))
- EMA’s CHMP backed EU marketing authorization for Biocon Biologics’ pertuzumab biosimilar Pebrilzo for HER2-positive breast cancer.
- European Commission to issue the final decision; the drug cannot be marketed in the EU until authorization is granted.
- Pebrilzo is positioned as the first monoclonal antibody biosimilar to win a CHMP recommendation under EMA’s tailored clinical approach.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 9AQ42RMPLL4SG54M) on September 21, 2026, and is solely responsible for the information contained therein.
- EMA’s CHMP backed EU marketing authorization for Biocon Biologics’ pertuzumab biosimilar Pebrilzo for HER2-positive breast cancer.
- European Commission to issue the final decision; the drug cannot be marketed in the EU until authorization is granted.
- Pebrilzo is positioned as the first monoclonal antibody biosimilar to win a CHMP recommendation under EMA’s tailored clinical approach.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 9AQ42RMPLL4SG54M) on September 21, 2026, and is solely responsible for the information contained therein.
- Biocon Biologics signed a 10-year partnership supply contract for pertuzumab in Brazil with Bahiafarma and Bionovis.
- Consortium received 100% allocation under Brazil’s Productive Development Partnership program for the HER2-positive breast cancer therapy.
- Deal grants exclusive access to Brazil’s public healthcare market, representing about 70% of national pertuzumab demand.
- Biocon Biologics to receive milestone payments plus a revenue share over the 10-year term.
- Contract includes phased localization of production in Brazil over the mid to long term.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 7P6IO80IKSATOWGL) on September 08, 2026, and is solely responsible for the information contained therein.
- Biocon Biologics signed a 10-year partnership supply contract for pertuzumab in Brazil with Bahiafarma and Bionovis.
- Consortium received 100% allocation under Brazil’s Productive Development Partnership program for the HER2-positive breast cancer therapy.
- Deal grants exclusive access to Brazil’s public healthcare market, representing about 70% of national pertuzumab demand.
- Biocon Biologics to receive milestone payments plus a revenue share over the 10-year term.
- Contract includes phased localization of production in Brazil over the mid to long term.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 7P6IO80IKSATOWGL) on September 08, 2026, and is solely responsible for the information contained therein.
Biocon's wholly owned subsidiary Biocon Biologics received marketing approval from Japan's Ministry of Health, Labour and Welfare for a pegfilgrastim biosimilar to Neulasta. Global Regulatory Partners Japan was named marketing authorisation holder, while Sandoz K.K. was to exclusively promote, sell and distribute the product in Japan. The approval added to Biocon's biosimilar portfolio, which accounted for 66% of operating revenue in the first quarter of FY27. Biocon reported FY26 revenue of ₹17,270 crore and launched five biosimilar products during that financial year.
Powered by Tijori
Biocon's wholly owned subsidiary Biocon Biologics received marketing approval from Japan's Ministry of Health, Labour and Welfare for a pegfilgrastim biosimilar to Neulasta. Global Regulatory Partners Japan was named marketing authorisation holder, while Sandoz K.K. was to exclusively promote, sell and distribute the product in Japan. The approval added to Biocon's biosimilar portfolio, which accounted for 66% of operating revenue in the first quarter of FY27. Biocon reported FY26 revenue of ₹17,270 crore and launched five biosimilar products during that financial year.
Powered by Tijori
** Shares of pharmaceutical company Biocon Limited BION.NS rise 1.5% to 418.20 rupees
** Company's U.S. subsidiary receives FDA approval for the Yesintek single-dose prefilled autoinjector in both the 45 mg/0.5 ml and 90 mg/ml formulations
** The approval covers a new autoinjector format for Yesintek, expanding treatment delivery options for patients, Biocon says
** The drug is approved for plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis
** "This supplemental approval enhances Biocon's comprehensive portfolio of immunology products in the United States," Biocon says
** Stock trades at forward 12-month PE of 46.86 vs industry median of 46.43
** Seven of 16 brokerages rate the stock "buy" or higher, three "hold" and six "sell" or lower; their median PT is 425 rupees
** YTD, Biocon stock up 6.1%
(Reporting by Abhinav Parmar in Bengaluru)
(([email protected];))
** Shares of pharmaceutical company Biocon Limited BION.NS rise 1.5% to 418.20 rupees
** Company's U.S. subsidiary receives FDA approval for the Yesintek single-dose prefilled autoinjector in both the 45 mg/0.5 ml and 90 mg/ml formulations
** The approval covers a new autoinjector format for Yesintek, expanding treatment delivery options for patients, Biocon says
** The drug is approved for plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis
** "This supplemental approval enhances Biocon's comprehensive portfolio of immunology products in the United States," Biocon says
** Stock trades at forward 12-month PE of 46.86 vs industry median of 46.43
** Seven of 16 brokerages rate the stock "buy" or higher, three "hold" and six "sell" or lower; their median PT is 425 rupees
** YTD, Biocon stock up 6.1%
(Reporting by Abhinav Parmar in Bengaluru)
(([email protected];))
** Shares of Indian biopharmaceutical company Biocon BION.NS rise 2.3% to 434.80 rupees
** Co on Wednesday posted 4.5x net profit y/y; rev from sale of products up 16.5%
** Stock on avg rated "hold" by 16 analysts; median PT is 420 rupees - LSEG-compiled data
** Stock up 10.4% YTD
(Reporting by Abhirami G in Bengaluru)
** Shares of Indian biopharmaceutical company Biocon BION.NS rise 2.3% to 434.80 rupees
** Co on Wednesday posted 4.5x net profit y/y; rev from sale of products up 16.5%
** Stock on avg rated "hold" by 16 analysts; median PT is 420 rupees - LSEG-compiled data
** Stock up 10.4% YTD
(Reporting by Abhirami G in Bengaluru)
Aug 5 (Reuters) - Indian biopharmaceutical company Biocon BION.NS reported a more than fourfold jump in first-quarter net profit on Wednesday on strong revenue growth from its biosimilars segment.
Consolidated net profit climbed to 1.41 billion rupees ($14.72 million) in the three months ended June 30.
Revenue from its biopharma segment jumped 17% to 36.15 billion rupees. The segment, which includes biosimilars and generic drugs, accounts for 83% of Biocon's overall revenue.
Biosimilars are lower-cost versions of complex biological drugs used to treat illnesses such as cancer, rheumatoid arthritis, psoriasis and diabetes.
A favourable policy environment for biosimilars and expanded manufacturing capabilities in the U.S. will help long-term opportunities across North America, the company's biggest market, said executive chairperson and founder Kiran Mazumdar-Shaw.
Biocon's services segment recorded a nearly 16% drop in revenue in the quarter.
Revenue from the sale of products was up by 16.5% from last year, while revenue from the sale of services was down about 15%.
Expenses grew 8.7%, largely due to an increase in cost of materials consumed.
Shares of Biocon closed 0.8% higher ahead of the results.
($1 = 95.1175 Indian rupees)
(Reporting by Abhirami G in Bengaluru; Editing by Janane Venkatraman)
Aug 5 (Reuters) - Indian biopharmaceutical company Biocon BION.NS reported a more than fourfold jump in first-quarter net profit on Wednesday on strong revenue growth from its biosimilars segment.
Consolidated net profit climbed to 1.41 billion rupees ($14.72 million) in the three months ended June 30.
Revenue from its biopharma segment jumped 17% to 36.15 billion rupees. The segment, which includes biosimilars and generic drugs, accounts for 83% of Biocon's overall revenue.
Biosimilars are lower-cost versions of complex biological drugs used to treat illnesses such as cancer, rheumatoid arthritis, psoriasis and diabetes.
A favourable policy environment for biosimilars and expanded manufacturing capabilities in the U.S. will help long-term opportunities across North America, the company's biggest market, said executive chairperson and founder Kiran Mazumdar-Shaw.
Biocon's services segment recorded a nearly 16% drop in revenue in the quarter.
Revenue from the sale of products was up by 16.5% from last year, while revenue from the sale of services was down about 15%.
Expenses grew 8.7%, largely due to an increase in cost of materials consumed.
Shares of Biocon closed 0.8% higher ahead of the results.
($1 = 95.1175 Indian rupees)
(Reporting by Abhirami G in Bengaluru; Editing by Janane Venkatraman)
Biocon Limited announced the commercial launch of Yesafili (aflibercept-jbvf), a US FDA-approved interchangeable biosimilar of Regeneron's Eylea 2 mg, in the United States. The product treats wet age-related macular degeneration and other serious eye conditions, and received FDA approval with interchangeable designation in May 2024. US sales of aflibercept reached roughly $5.89 billion in 2023. The launch extends Biocon's global biosimilar portfolio to 12 commercialized products, part of a broader FY26 acceleration that has included launches of Yesintek, Kirsty and other biosimilars.
Powered by Tijori
Biocon Limited announced the commercial launch of Yesafili (aflibercept-jbvf), a US FDA-approved interchangeable biosimilar of Regeneron's Eylea 2 mg, in the United States. The product treats wet age-related macular degeneration and other serious eye conditions, and received FDA approval with interchangeable designation in May 2024. US sales of aflibercept reached roughly $5.89 billion in 2023. The launch extends Biocon's global biosimilar portfolio to 12 commercialized products, part of a broader FY26 acceleration that has included launches of Yesintek, Kirsty and other biosimilars.
Powered by Tijori
Biocon Limited announced the US commercial launch of Yesafili, its biosimilar to Regeneron's Eylea (aflibercept) 2 mg, on August 3. The product is now available in the United States as an FDA-approved interchangeable biosimilar, allowing substitution at the pharmacy level. US sales of aflibercept reached approximately $5.89 billion in 2023, giving the launch a substantial addressable market among the roughly 19.8 million Americans living with age-related macular degeneration. Yesafili was among the five biosimilar launches Biocon counted in fiscal 2026, and the company has now commercialized 12 biosimilar products globally.
Powered by Tijori
Biocon Limited announced the US commercial launch of Yesafili, its biosimilar to Regeneron's Eylea (aflibercept) 2 mg, on August 3. The product is now available in the United States as an FDA-approved interchangeable biosimilar, allowing substitution at the pharmacy level. US sales of aflibercept reached approximately $5.89 billion in 2023, giving the launch a substantial addressable market among the roughly 19.8 million Americans living with age-related macular degeneration. Yesafili was among the five biosimilar launches Biocon counted in fiscal 2026, and the company has now commercialized 12 biosimilar products globally.
Powered by Tijori
Aug 3 (Reuters) - Biocon Ltd BION.NS:
BIOCON ANNOUNCES U.S. COMMERCIAL LAUNCH OF YESAFILI™, A BIOSIMILAR TO REGENERON’S EYLEA® 2 MG
Source text: ID:nBw3jMV5a
Further company coverage: BION.NS
(([email protected];))
Aug 3 (Reuters) - Biocon Ltd BION.NS:
BIOCON ANNOUNCES U.S. COMMERCIAL LAUNCH OF YESAFILI™, A BIOSIMILAR TO REGENERON’S EYLEA® 2 MG
Source text: ID:nBw3jMV5a
Further company coverage: BION.NS
(([email protected];))
July 16 (Reuters) - Biocon Ltd BION.NS:
BIOCON - BIOCON MALAYSIA RECEIVES EMA APPROVAL FOR NEW DRUG PRODUCT FILL FINISH UNIT FOR INSULINS
Source text: ID:nnAZN4T822N
Further company coverage: BION.NS
(([email protected];))
July 16 (Reuters) - Biocon Ltd BION.NS:
BIOCON - BIOCON MALAYSIA RECEIVES EMA APPROVAL FOR NEW DRUG PRODUCT FILL FINISH UNIT FOR INSULINS
Source text: ID:nnAZN4T822N
Further company coverage: BION.NS
(([email protected];))
Mylan Inc. disclosed on Tuesday that it sold its entire 5.64 percent stake in Biocon, selling 9.19 crore shares on the open market on July 14. The sale, worth approximately ₹4,000 crore at prevailing prices, completely exited the American pharmaceutical company from the Indian biopharmaceutical firm. Mylan and Biocon have shared a long-standing partnership in biosimilars, with Mylan previously holding the stake as a strategic investor. The disposal was disclosed under Regulation 29(2) of the SEBI Takeover Regulations. Mylan was not part of Biocon’s promoter group and had held the 5.64 percent stake without any encumbrances. Following the transaction, Mylan no longer holds any equity shares in the company. The exit may prompt investor questions about the future of the biosimilars alliance between the two firms.
Powered by Tijori
Mylan Inc. disclosed on Tuesday that it sold its entire 5.64 percent stake in Biocon, selling 9.19 crore shares on the open market on July 14. The sale, worth approximately ₹4,000 crore at prevailing prices, completely exited the American pharmaceutical company from the Indian biopharmaceutical firm. Mylan and Biocon have shared a long-standing partnership in biosimilars, with Mylan previously holding the stake as a strategic investor. The disposal was disclosed under Regulation 29(2) of the SEBI Takeover Regulations. Mylan was not part of Biocon’s promoter group and had held the 5.64 percent stake without any encumbrances. Following the transaction, Mylan no longer holds any equity shares in the company. The exit may prompt investor questions about the future of the biosimilars alliance between the two firms.
Powered by Tijori
** Shares of Biocon BION.NS rise 5.3% to 432.85 rupees
** Nearly 46 mln shares of BION change hands via block deal on NSE at 400 rupees per share - exchange data showed
** Mylan Inc, part of healthcare company Viatris VTRS.O, planned to sell up to 92 mln shares in BION, worth up to 34.81 bln rupees ($362.1 mln), as per term sheet seen by Reuters
** YTD, BION up ~10%
($1 = 96.1350 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Biocon BION.NS rise 5.3% to 432.85 rupees
** Nearly 46 mln shares of BION change hands via block deal on NSE at 400 rupees per share - exchange data showed
** Mylan Inc, part of healthcare company Viatris VTRS.O, planned to sell up to 92 mln shares in BION, worth up to 34.81 bln rupees ($362.1 mln), as per term sheet seen by Reuters
** YTD, BION up ~10%
($1 = 96.1350 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
Updates with company's response in bullet 4
By Yantoultra Ngui
SINGAPORE, July 13 (Reuters) - Mylan Inc, part of a global healthcare company Viatris VTRS.O, plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd BION.NS, worth up to 34.81 billion Indian rupees ($363 million), according to a term sheet seen by Reuters.
The sale represents up to 5.64% of Biocon's outstanding shares. It is a secondary sale, meaning the shares are being sold by an existing investor and Biocon will not receive the proceeds.
The offer floor price is 378.50 rupees per share, a 7.9% discount to Biocon's last close of 410.95 rupees on Monday.
Biocon did not immediately respond to an emailed request seeking comment.
"We do not comment on market rumors or speculation," Viatris said in response to a Reuters request for comment.
Citigroup Global Markets India and Jefferies India are joint bookrunners and brokers for the deal.
($1 = 95.6200 Indian rupees)
(Reporting by Yantoultra Ngui
Editing by Tomasz Janowski)
(([email protected];))
Updates with company's response in bullet 4
By Yantoultra Ngui
SINGAPORE, July 13 (Reuters) - Mylan Inc, part of a global healthcare company Viatris VTRS.O, plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd BION.NS, worth up to 34.81 billion Indian rupees ($363 million), according to a term sheet seen by Reuters.
The sale represents up to 5.64% of Biocon's outstanding shares. It is a secondary sale, meaning the shares are being sold by an existing investor and Biocon will not receive the proceeds.
The offer floor price is 378.50 rupees per share, a 7.9% discount to Biocon's last close of 410.95 rupees on Monday.
Biocon did not immediately respond to an emailed request seeking comment.
"We do not comment on market rumors or speculation," Viatris said in response to a Reuters request for comment.
Citigroup Global Markets India and Jefferies India are joint bookrunners and brokers for the deal.
($1 = 95.6200 Indian rupees)
(Reporting by Yantoultra Ngui
Editing by Tomasz Janowski)
(([email protected];))
May 11 (Reuters) - Biocon Ltd BION.NS:
BIOCON - BIOCON PHARMA RECEIVES HEALTH CANADA APPROVAL FOR MICAFUNGIN FOR INJECTION, USP, 50 MG AND 100 MG
Source text: ID:nnAZN4SVCE2
Further company coverage: BION.NS
(([email protected];))
May 11 (Reuters) - Biocon Ltd BION.NS:
BIOCON - BIOCON PHARMA RECEIVES HEALTH CANADA APPROVAL FOR MICAFUNGIN FOR INJECTION, USP, 50 MG AND 100 MG
Source text: ID:nnAZN4SVCE2
Further company coverage: BION.NS
(([email protected];))
** Biocon BION.NS gains 2.68% to 392.50 rupees
** Drugmaker's Q4 consol net income rises ~2.6% y/y on growth led by biosimilars, generics businesses
** Revenue from generics up 13% y/y, biosimilars up 12%
** EBITDA rises 29% y/y
** Net profit before exceptional items rises 64% y/y; reported net profit drops ~63.5% y/y, hit by one-off exceptional charges
** Stock rated "buy" on average; median PT is 425 rupees, per data compiled by LSEG
** YTD, BION down ~1.36%, Nifty Pharma .NIPHARM up ~6%
(Reporting by Bipasha Dey in Bengaluru)
(([email protected];))
** Biocon BION.NS gains 2.68% to 392.50 rupees
** Drugmaker's Q4 consol net income rises ~2.6% y/y on growth led by biosimilars, generics businesses
** Revenue from generics up 13% y/y, biosimilars up 12%
** EBITDA rises 29% y/y
** Net profit before exceptional items rises 64% y/y; reported net profit drops ~63.5% y/y, hit by one-off exceptional charges
** Stock rated "buy" on average; median PT is 425 rupees, per data compiled by LSEG
** YTD, BION down ~1.36%, Nifty Pharma .NIPHARM up ~6%
(Reporting by Bipasha Dey in Bengaluru)
(([email protected];))
May 5 (Reuters) - Biocon founder Kiran Mazumdar-Shaw plans a gradual leadership transition over the next five years, with her niece Claire Mazumdar expected to take over as chair in a phased manner, she told Reuters.
The succession plan was first reported by business magazine Fortune India in an interview with Mazumdar-Shaw.
(Reporting by Rishika Sadam; Writing by Surbhi Misra ; Editing by Nivedita Bhattacharjee)
(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))
May 5 (Reuters) - Biocon founder Kiran Mazumdar-Shaw plans a gradual leadership transition over the next five years, with her niece Claire Mazumdar expected to take over as chair in a phased manner, she told Reuters.
The succession plan was first reported by business magazine Fortune India in an interview with Mazumdar-Shaw.
(Reporting by Rishika Sadam; Writing by Surbhi Misra ; Editing by Nivedita Bhattacharjee)
(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))
May 4 (Reuters) - Biocon Ltd BION.NS:
BIOCON - BOARD TO CONSIDER INVESTMENT IN BIOCON BIOLOGICS VIA PREFERENTIAL EQUITY ALLOTMENT
Source text: ID:nBSE3FXwyN
Further company coverage: BION.NS
(([email protected];))
May 4 (Reuters) - Biocon Ltd BION.NS:
BIOCON - BOARD TO CONSIDER INVESTMENT IN BIOCON BIOLOGICS VIA PREFERENTIAL EQUITY ALLOTMENT
Source text: ID:nBSE3FXwyN
Further company coverage: BION.NS
(([email protected];))
April 30 (Reuters) - Biocon Ltd BION.NS:
BIOCON - U.S. FDA COMPLETES PRE-LICENSE INSPECTION AT BIOCON'S BIOSIMILARS SITE IN BENGALURU
BIOCON - U.S. FDA ISSUES FORM 483 WITH FIVE OBSERVATIONS AFTER INSPECTION
Source text: ID:nNSE5Z9qN5
Further company coverage: BION.NS
(([email protected];))
April 30 (Reuters) - Biocon Ltd BION.NS:
BIOCON - U.S. FDA COMPLETES PRE-LICENSE INSPECTION AT BIOCON'S BIOSIMILARS SITE IN BENGALURU
BIOCON - U.S. FDA ISSUES FORM 483 WITH FIVE OBSERVATIONS AFTER INSPECTION
Source text: ID:nNSE5Z9qN5
Further company coverage: BION.NS
(([email protected];))
April 21 (Reuters) - Biocon Ltd BION.NS:
RECEIVES HEALTH CANADA APPROVAL FOR BOSAYA AND VEVZUO BIOSIMILARS
Source text: ID:nBSE2TxjhJ
Further company coverage: BION.NS
(([email protected];))
April 21 (Reuters) - Biocon Ltd BION.NS:
RECEIVES HEALTH CANADA APPROVAL FOR BOSAYA AND VEVZUO BIOSIMILARS
Source text: ID:nBSE2TxjhJ
Further company coverage: BION.NS
(([email protected];))
April 8 (Reuters) - Biocon Ltd BION.NS:
BIOCON - UNIT RECEIVES U.S. FDA APPROVAL FOR DAPAGLIFLOZIN TABLETS, 5 MG AND 10 MG
Source text: ID:nBSE8pdZnk
Further company coverage: BION.NS
(([email protected];;))
April 8 (Reuters) - Biocon Ltd BION.NS:
BIOCON - UNIT RECEIVES U.S. FDA APPROVAL FOR DAPAGLIFLOZIN TABLETS, 5 MG AND 10 MG
Source text: ID:nBSE8pdZnk
Further company coverage: BION.NS
(([email protected];;))
April 7 (Reuters) - Biocon Ltd BION.NS:
BIOCON - ANNOUNCES U.S. COMMERCIAL LAUNCH OF BOSAYA AND AUKELSO, DENOSUMAB BIOSIMILARS
Source text: ID:nBSE10Z4f4
Further company coverage: BION.NS
(([email protected];;))
April 7 (Reuters) - Biocon Ltd BION.NS:
BIOCON - ANNOUNCES U.S. COMMERCIAL LAUNCH OF BOSAYA AND AUKELSO, DENOSUMAB BIOSIMILARS
Source text: ID:nBSE10Z4f4
Further company coverage: BION.NS
(([email protected];;))
- Biodexa partnered with Syngene to manufacture MTX240 active ingredient plus finished dosage form for GMP clinical trial supply.
- Work supports Biodexa plan to file an IND and start a Phase 1b/2a study in GIST toward end of 2026.
- MTX240 targets TKI-resistant GIST via a molecular-glue mechanism designed to trigger apoptosis independent of KIT signaling.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604020830PRIMZONEFULLFEED1001173895) on April 02, 2026, and is solely responsible for the information contained therein.
- Biodexa partnered with Syngene to manufacture MTX240 active ingredient plus finished dosage form for GMP clinical trial supply.
- Work supports Biodexa plan to file an IND and start a Phase 1b/2a study in GIST toward end of 2026.
- MTX240 targets TKI-resistant GIST via a molecular-glue mechanism designed to trigger apoptosis independent of KIT signaling.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604020830PRIMZONEFULLFEED1001173895) on April 02, 2026, and is solely responsible for the information contained therein.
March 27 (Reuters) - Biocon Ltd BION.NS:
BIOCON - SIDDHARTH MITTAL TO STEP DOWN AS CEO AND MANAGING DIRECTOR EFFECTIVE MARCH 31, 2026
BIOCON - APPOINTS SHREEHAS PRADEEP TAMBE AS CEO AND MANAGING DIRECTOR EFFECTIVE APRIL 1, 2026
BIOCON - MUKESH KAMATH TO STEP DOWN AS INTERIM CHIEF FINANCIAL OFFICER
BIOCON - APPOINTS KEDAR NARAYAN UPADHYE AS CHIEF FINANCIAL OFFICER EFFECTIVE APRIL 1, 2026
BIOCON - APPOINTS KEDAR NARAYAN UPADHYE AS CHIEF FINANCIAL OFFICER
Source text: ID:nBSE5rJf10
Further company coverage: BION.NS
(([email protected];))
March 27 (Reuters) - Biocon Ltd BION.NS:
BIOCON - SIDDHARTH MITTAL TO STEP DOWN AS CEO AND MANAGING DIRECTOR EFFECTIVE MARCH 31, 2026
BIOCON - APPOINTS SHREEHAS PRADEEP TAMBE AS CEO AND MANAGING DIRECTOR EFFECTIVE APRIL 1, 2026
BIOCON - MUKESH KAMATH TO STEP DOWN AS INTERIM CHIEF FINANCIAL OFFICER
BIOCON - APPOINTS KEDAR NARAYAN UPADHYE AS CHIEF FINANCIAL OFFICER EFFECTIVE APRIL 1, 2026
BIOCON - APPOINTS KEDAR NARAYAN UPADHYE AS CHIEF FINANCIAL OFFICER
Source text: ID:nBSE5rJf10
Further company coverage: BION.NS
(([email protected];))
Feb 24 (Reuters) - Biocon Ltd BION.NS:
BIOCON OBTAINS APPROVAL FOR WEIGHT MANAGEMENT DRUG LIRAGLUTIDE IN THE UNITED STATES
Source text: [ID:]
Further company coverage: BION.NS
(([email protected];;))
Feb 24 (Reuters) - Biocon Ltd BION.NS:
BIOCON OBTAINS APPROVAL FOR WEIGHT MANAGEMENT DRUG LIRAGLUTIDE IN THE UNITED STATES
Source text: [ID:]
Further company coverage: BION.NS
(([email protected];;))
Repeats story from 13th Feburary with no changes to text
By Rishika Sadam
Feb 16 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.
The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.
Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.
It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.
The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.
"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.
In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.
The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.
Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.
India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.
(Reporting by Rishika Sadam; Editing by Tasim Zahid)
(([email protected];))
Repeats story from 13th Feburary with no changes to text
By Rishika Sadam
Feb 16 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.
The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.
Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.
It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.
The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.
"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.
In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.
The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.
Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.
India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.
(Reporting by Rishika Sadam; Editing by Tasim Zahid)
(([email protected];))
By Rishika Sadam
Feb 13 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.
The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.
Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.
It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.
The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.
"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.
In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.
The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.
Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.
India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.
(Reporting by Rishika Sadam; Editing by Tasim Zahid)
(([email protected];))
By Rishika Sadam
Feb 13 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.
The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.
Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.
Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.
It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.
The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.
"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.
In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.
The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.
Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.
India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.
(Reporting by Rishika Sadam; Editing by Tasim Zahid)
(([email protected];))
Feb 12 (Reuters) - Biocon Ltd BION.NS:
Q3 CONSOL NET PROFIT 1.44 BILLION RUPEES
Q3 CONSOL TOTAL INCOME 42.9 BILLION RUPEES
ONE-TIME CHARGE OF 2.93 BILLION RUPEES IN Q3
Source text: [ID:]
Further company coverage: BION.NS
(([email protected];;))
Feb 12 (Reuters) - Biocon Ltd BION.NS:
Q3 CONSOL NET PROFIT 1.44 BILLION RUPEES
Q3 CONSOL TOTAL INCOME 42.9 BILLION RUPEES
ONE-TIME CHARGE OF 2.93 BILLION RUPEES IN Q3
Source text: [ID:]
Further company coverage: BION.NS
(([email protected];;))
Feb 7 - Biocon Biologics Ltd BIOC.NS:
BIOCON - FITCH RATINGS UPS UNIT BIOCON BIOLOGICS OUTLOOK TO POSITIVE FROM STABLE
Source text: [ID:]
Further company coverage: BIOC.NS
Feb 7 - Biocon Biologics Ltd BIOC.NS:
BIOCON - FITCH RATINGS UPS UNIT BIOCON BIOLOGICS OUTLOOK TO POSITIVE FROM STABLE
Source text: [ID:]
Further company coverage: BIOC.NS
More Mid Cap Ideas
See similar 'Mid' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Biocon do?
Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe.
Who are the competitors of Biocon?
Biocon major competitors are Concord Biotech, Advanced Enzyme Tech, Fermenta Biotech, Alkem Laboratories, Abbott India, Gland Pharma, Ipca Laboratories. Market Cap of Biocon is ₹58,995 Crs. While the median market cap of its peers are ₹47,360 Crs.
Is Biocon financially stable compared to its competitors?
Biocon seems to be less financially stable compared to its competitors. Altman Z score of Biocon is 2.28 and is ranked 8 out of its 8 competitors.
Does Biocon pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Biocon latest dividend payout ratio is 21.02% and 3yr average dividend payout ratio is 10.94%
How has Biocon allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Biocon balance sheet?
Balance sheet of Biocon is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Biocon improving?
No, profit is decreasing. The profit of Biocon is ₹340 Crs for TTM, ₹386 Crs for Mar 2026 and ₹1,013 Crs for Mar 2025.
Is the debt of Biocon increasing or decreasing?
Yes, The net debt of Biocon is increasing. Latest net debt of Biocon is ₹12,688 Crs as of Sep-26. This is greater than Mar-26 when it was ₹8,438 Crs.
Is Biocon stock expensive?
Yes, Biocon is expensive. Latest PE of Biocon is 130, while 3 year average PE is 82.22. Also latest EV/EBITDA of Biocon is 20.3 while 3yr average is 18.38.
Has the share price of Biocon grown faster than its competition?
Biocon has given better returns compared to its competitors. Biocon has grown at ~17.73% over the last 3yrs while peers have grown at a median rate of 4.91%
Is the promoter bullish about Biocon?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Biocon is 44.68% and last quarter promoter holding is 44.68%.
Are mutual funds buying/selling Biocon?
The mutual fund holding of Biocon is increasing. The current mutual fund holding in Biocon is 22.08% while previous quarter holding is 15.47%.